Lindsay McKenna

The FDA’s concession conundrum

Can regulatory incentives promote responsible TB drug development?

Read More →

Improving outcomes for adolescents with drug-resistant tuberculosis

Dear Editor,

Read More →

Punked by pharma: Public funds for private products

Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment?  

Read More →

Urgency needed in the global response to drug-resistant tuberculosis

In the second of two linked posts (you can read the first one here), Lindsay McKenna and Colleen Daniels of Treatment Action Group (TAG) describe the importance of access to timely diagnosis and appropriate treatment for patients with drug-resistant tuberculosis and demand that urgency be returned to the global DR-TB response.

Read More →

U.S.: An obligatory overhaul to address domestic TB drug shortages

Drug shortages, especially of tuberculosis (TB) drugs, have become increasingly common in the United States. Over the past year alone, the U.S. Centers for Disease Control and Prevention (CDC) has reported shortages (also referred to as stock-outs or supply interruptions) of various TB products including second-line injectables (capreomycin and amikacin), required to fight drug-resistant TB (DR-TB)­, and tubersol and aplisol, important products for TB diagnosis.

Read More →

Page 1 of 1 · Total posts: 5

1